These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32771907)

  • 1. CRISPR/Cas9 gene editing of a SOX9 reporter human iPSC line to produce two TRPV4 patient heterozygous missense mutant iPSC lines, MCRIi001-A-3 (TRPV4 p.F273L) and MCRIi001-A-4 (TRPV4 p.P799L).
    Nur Patria Y; Stenta T; Lilianty J; Rowley L; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
    Stem Cell Res; 2020 Oct; 48():101942. PubMed ID: 32771907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation of a SOX9-tdTomato reporter human iPSC line, MCRIi001-A-2, using CRISPR/Cas9 editing.
    Nur Patria Y; Lilianty J; Elefanty AG; Stanley EG; Labonne T; Bateman JF; Lamandé SR
    Stem Cell Res; 2020 Jan; 42():101689. PubMed ID: 31884373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of a heterozygous COL2A1 (p.R989C) spondyloepiphyseal dysplasia congenita mutation iPSC line, MCRIi001-B, using CRISPR/Cas9 gene editing.
    Lilianty J; Nur Patria Y; Stanley EG; Elefanty AG; Bateman JF; Lamandé SR
    Stem Cell Res; 2020 May; 45():101843. PubMed ID: 32446218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CRISPR/Cas9 editing to generate a heterozygous COL2A1 p.G1170S human chondrodysplasia iPSC line, MCRIi019-A-2, in a control iPSC line, MCRIi019-A.
    Kung LHW; Sampurno L; Yammine KM; Graham A; McDonald P; Bateman JF; Shoulders MD; Lamandé SR
    Stem Cell Res; 2020 Oct; 48():101962. PubMed ID: 33002832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing.
    Hosseini Far H; Patria YN; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
    Stem Cell Res; 2019 May; 37():101449. PubMed ID: 31075690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of two ISL1-tdTomato reporter human induced pluripotent stem cell lines using CRISPR-Cas9 genome editing.
    Tsukamoto S; Nakade K; Wakabayashi T; Nakashima K; Takami M; Hemmi Y; Kuramochi Y; Shimizu T; Arai Y; Matsuo-Takasaki M; Noguchi M; Nakamura Y; Miwa Y; Hayashi Y
    Stem Cell Res; 2021 May; 53():102363. PubMed ID: 34087992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of a heterozygous COL2A1 (p.G1113C) hypochondrogenesis mutation iPSC line, MCRIi019-A-7, using CRISPR/Cas9 gene editing.
    Lilianty J; Bateman JF; Lamandé SR
    Stem Cell Res; 2021 Oct; 56():102515. PubMed ID: 34543885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation of heterozygous (MCRIi031-A-1) and homozygous (MCRIi031-A-2) SOX9 knockout human iPSC lines.
    Pachernegg S; Robevska G; G A Ferreira L; van den Bergen JA; Vlahos K; Howden SE; Sinclair AH; Ayers KL
    Stem Cell Res; 2024 Sep; 79():103484. PubMed ID: 38924973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation of a gene corrected human isogenic IBMS-iPSC-014-C from polycystic-kidney-disease induced pluripotent stem cell line using CRISPR/Cas9.
    Liu CL; Huang CY; Chen HC; Lu HE; Hsieh PCH; Lee JJ
    Stem Cell Res; 2020 May; 45():101784. PubMed ID: 32361310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generating an iPSC line (with isogenic control) from the PBMCs of an ACTA1 (p.Gly148Asp) nemaline myopathy patient.
    Houweling PJ; Coles CA; Tiong CF; Nielsen B; Graham A; McDonald P; Suter A; Piers AT; Forbes R; Ryan MM; Howden SE; Lamandé SR; North KN
    Stem Cell Res; 2021 Jul; 54():102429. PubMed ID: 34157503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of Hirschsprung-Associated Mutations in Human Induced Pluripotent Stem Cells Via Clustered Regularly Interspaced Short Palindromic Repeats/Cas9, Restores Neural Crest Cell Function.
    Lai FP; Lau ST; Wong JK; Gui H; Wang RX; Zhou T; Lai WH; Tse HF; Tam PK; Garcia-Barcelo MM; Ngan ES
    Gastroenterology; 2017 Jul; 153(1):139-153.e8. PubMed ID: 28342760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
    Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
    Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation of a human Neurochondrin deficient iPSC line KICRi002-A-3 using CRISPR/Cas9.
    Fatima A; Schuster J; Akram T; Sobol M; Hoeber J; Dahl N
    Stem Cell Res; 2020 Apr; 44():101758. PubMed ID: 32203915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G>T iPSC line and an isogenic control iPSC line.
    Howden S; Hosseini Far H; Motazedian A; Elefanty AG; Stanley EG; Lamandé SR; Bateman JF
    Stem Cell Res; 2019 Jul; 38():101453. PubMed ID: 31082677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene Editing in Human Induced Pluripotent Stem Cells Using Doxycycline-Inducible CRISPR-Cas9 System.
    Thamodaran V; Rani S; Velayudhan SR
    Methods Mol Biol; 2022; 2454():755-773. PubMed ID: 33830454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors.
    Jin Y; Shen Y; Su X; Weintraub N; Tang Y
    J Vis Exp; 2019 Sep; (151):. PubMed ID: 31566614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9 Genome Editing: A Promising Tool for Therapeutic Applications of Induced Pluripotent Stem Cells.
    Zhang Y; Sastre D; Wang F
    Curr Stem Cell Res Ther; 2018; 13(4):243-251. PubMed ID: 29446747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
    Ma L; Wu Z; Tang Q; Ji X; Mei Y; Peng T; Xu Q; Zhou W; Xiong M
    Stem Cell Res; 2021 May; 53():102305. PubMed ID: 33813175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of a gene corrected human isogenic iPSC line (CPGHi002-A-1) from a DDOD patient with heterozygous c.1516 C>T mutation in the ATP6V1B2 gene.
    Gao X; Qiu SW; Wang WQ; Kang DY; Su N; Dai P; Yuan YY
    Stem Cell Res; 2021 May; 53():102271. PubMed ID: 33714068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation and characterization of a human iPSC line and gene-corrected isogenic line derived from a patient with a CELF2 gene mutation.
    Hua M; Williams L; Burns K; Liu S; Ellis J; Innes AM; McPherson M; Yang G
    Stem Cell Res; 2024 Apr; 76():103344. PubMed ID: 38364506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.